Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial. [PDF]
Wu R +19 more
europepmc +1 more source
The Role of IFN-γ-Mediated Immune Cell Crosstalk in the Pathogenesis of Aplastic Anemia. [PDF]
Tan S, Li Y, Chen Y, Sun W.
europepmc +1 more source
B cell-driven refractory hemocytopenia in immune checkpoint inhibitor therapy: a report of two cases. [PDF]
Li F +6 more
europepmc +1 more source
Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study. [PDF]
Yuan Y, Tong Q, Liu JH, Kang Y.
europepmc +1 more source
Optimization of thrombopoietin mimetic peptide fusion proteins with albumin-binding domain for enhanced bioactivity and extended half-life. [PDF]
Ying J +5 more
europepmc +1 more source
Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis. [PDF]
Zhang X, Zhao Y, Yang M, Feng X.
europepmc +1 more source
Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia. [PDF]
Harris EM +6 more
europepmc +1 more source
Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag. [PDF]
Sau A +5 more
europepmc +1 more source
Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment. [PDF]
Song AB, Al-Samkari H.
europepmc +1 more source

